s
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
20-06-2024, 11:41
CHENGDU, China, June 20, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang’s team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled “A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia” in the New England Journal of Medicine. This is an investigator-initiated, single-arm, open-label phase I/II study […] L'articolo Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM proviene da La Ragione.
CONTINUA A LEGGERE
14
0
0
Guarda anche
La Ragione
01:43
Tripletta Thuram, Inter batte 3-2 il Torino
La Ragione
Ieri, 21:43
Manovra, Tajani “Extraprofitto incomprensibile, concetto extraterrestre”
La Ragione
Ieri, 19:43
Confesercenti “Tetti agli affitti per le attività di prossimità”
La Ragione
Ieri, 19:43
Scontri a Roma tra i manifestanti pro Palestina e le forze dell’ordine
La Ragione
Ieri, 18:52
Alimentazione, esperti: “Con esercizio fisico pilastri longevità sana”
La Ragione
Ieri, 18:12